NVO

The company traces its origin to 1923, when the Danish Nobel laureate August Krogh secured permission from the Toronto researchers who discovered insulin to manufacture it in Scandinavia. Krogh, working with the physician Hans Christian Hagedorn, founded Nordisk Insulinlaboratorium. Two years later, two former Nordisk employees, the brothers Harald and Thorvald Pedersen, founded a competing insulin maker called Novo. For more than six decades the two Danish firms developed insulin in parallel, sometimes cooperating and often competing, building deep manufacturing and protein-science know-how in the process. They merged in 1989 to form Novo Nordisk A/S, creating what was then the world's largest insulin producer. The diabetes franchise remained the company's spine for the next thirty years through successive generations of human and analog insulins and the insulin pens that made daily injection routine for millions of patients. That long apprenticeship in producing, formulating, and delivering injectable proteins at industrial scale is the foundation everything else rests on.

The decisive turn came with the GLP-1 receptor agonists, a class of injectable peptides that mimic a gut hormone the body releases after eating. The hormone prompts the pancreas to release insulin, slows the emptying of the stomach, and signals fullness to the brain. Novo Nordisk commercialized an early version, liraglutide, sold as Victoza for diabetes and later Saxenda for weight loss. The breakthrough product was semaglutide, a longer-acting molecule that could be dosed once a week. Launched as Ozempic for type 2 diabetes in the late 2010s, it quickly became a blockbuster on the strength of strong blood-sugar control and meaningful weight reduction. The company then ran large trials of higher-dose semaglutide specifically for obesity, won approval for Wegovy in 2021, and in doing so helped convert obesity from a lifestyle concern into a treatable chronic disease in the eyes of regulators, physicians, and payers. Demand outran anything the company had forecast. For the first time a pill-free, prescription weight-loss treatment delivered results that rivaled bariatric surgery for some patients, and the cultural and commercial response was enormous.

Novo Nordisk sells these products through a relatively concentrated portfolio. Diabetes care, spanning the insulins, the GLP-1 drugs Ozempic and Rybelsus, and related devices, remains the larger revenue base. Obesity care, led by Wegovy, is the faster-growing segment and the reason the company became one of Europe's most valuable enterprises. A smaller rare-disease unit covers hemophilia and certain hormone disorders, a legacy of the company's protein expertise. Rybelsus deserves note because it is an oral form of semaglutide, a technically difficult achievement given that peptides are normally destroyed in the digestive tract. In December 2025 the company extended that work when the United States approved an oral version of Wegovy, the first oral GLP-1 cleared for weight management, with a launch planned for early 2026. The ability to deliver a peptide in pill form, if it scales, could broaden the market well beyond patients willing to inject.

The economic engine has three reinforcing parts. The first is the science itself, a portfolio of patented molecules with years of exclusivity and clinical data showing benefits beyond weight and blood sugar, including reduced cardiovascular risk, which strengthens the case for insurance coverage. The second is manufacturing. Producing semaglutide at the scale the world suddenly demanded is genuinely hard, requiring specialized capacity for synthesizing the peptide and for the sterile filling of injection pens. Novo Nordisk has spent heavily to expand this base, including an agreement in 2024 to acquire three fill-finish plants connected to the roughly 16.5 billion dollar purchase of contract manufacturer Catalent by its parent foundation's investment arm. That supply capacity is itself a competitive moat, because a rival with an approved drug still cannot sell what it cannot make. The third part is the accumulated organizational knowledge of peptide chemistry, formulation, and device engineering, a base of expertise that is difficult and slow for competitors to replicate.

For most of its modern history Novo Nordisk faced limited direct competition in its core franchise. That changed decisively with Eli Lilly. The American company developed tirzepatide, a molecule that activates two gut-hormone receptors rather than one, sold as Mounjaro for diabetes and Zepbound for obesity. In several head-to-head and cross-trial comparisons tirzepatide produced greater average weight loss than semaglutide, and Lilly invested aggressively in its own manufacturing. Over the course of 2025 Lilly's combined obesity and diabetes sales pulled ahead of Novo Nordisk's, and Lilly took the lead in new United States prescriptions, helped in part by Novo Nordisk's earlier struggles to supply enough Wegovy to meet demand. The shortage also allowed compounding pharmacies to sell cheaper copies of semaglutide for a time, eroding both price and brand. The contest between the two firms now defines the category, and it is being fought on efficacy, on supply, on price, and increasingly on the convenience of oral dosing.

Leadership changed during this pressure. In August 2025 the board appointed Maziar Mike Doustdar as president and chief executive officer, succeeding Lars Fruergaard Joergensen, who had led the company through the GLP-1 ascent and the subsequent setbacks. Doustdar had run the company's International Operations, the business outside the United States and a handful of core markets, which more than doubled its sales under his stewardship. His appointment, fully endorsed by the controlling foundation, signaled a desire for commercial execution and discipline after a period in which the company appeared to lose ground despite owning a category it had helped create. The board itself was reshaped later in 2025 as the foundation's investment arm moved to assert greater control through a contested shareholder vote, an unusual public display of the owner's hand in a company normally run at arm's length.

The strategy from here centers on defending and extending the semaglutide franchise while finding the next molecule. That means scaling oral Wegovy, broadening the approved uses of semaglutide into adjacent conditions where GLP-1 drugs show benefit, and pushing next-generation candidates through the pipeline. The most watched of those candidates, a combination of semaglutide and an amylin analog called CagriSema, was meant to leapfrog the competition but disappointed in trials reported across late 2024 and 2025, delivering weight loss below the company's own targets and below what investors expected against Lilly. Those misses, more than anything else, drove the share price down sharply through 2025 and raised the question of whether Novo Nordisk can produce a clearly superior follow-up rather than incremental improvements. The company is also expected to lean on business development and acquisitions to refill the pipeline, given how much future revenue is concentrated in a single mechanism.

The risks are specific and substantial. Concentration is the central one. A very large share of revenue depends on semaglutide, so any safety signal, manufacturing disruption, or pricing shock to that one franchise would be severe. Patent expiration looms in the next several years, after which lower-cost competition will arrive. Pricing is a persistent pressure, with United States payers and political actors pushing for lower obesity-drug prices, and with the sheer size of the eligible population making full reimbursement a fiscal question for health systems worldwide. Competition from Lilly is direct and well-funded, and a wave of additional GLP-1 entrants is in development. Clinical risk is real, as the CagriSema results showed, and the next generation may not deliver the margin of superiority the market wants. The ownership structure, while a source of stability, also concentrates control in a foundation whose priorities may not always align with minority shareholders, and United States investors hold an ADR one further step removed from that governance.

The forward question for an investor is whether Novo Nordisk's century of peptide expertise and its heavy investment in manufacturing capacity can be converted into durable leadership of a market it pioneered, or whether it has ceded the front of a race it started. The company owns one of the most commercially successful drug franchises in history and a control structure built for the long term, yet it enters that future as a challenger to Lilly on efficacy and prescription share rather than the unquestioned leader it recently was. The bet rests on execution under new leadership, on scaling the oral formulation, and on whether the pipeline can produce a genuine next act. The upside is participation in a chronic-disease market that may expand for years. The tension is that the durable assets, science, scale, and ownership, are now set against a stronger rival and a thinner cushion of clinical superiority than the company enjoyed at its peak.